Dianthus Therapeutics, Inc. (DNTH): R&D Expense
$145.64M
Year ended 2025-12-31
$175.60M
Trailing 12 months to 2026-06-30
+70.5%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $145.64M | +75.2% | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $83.11M | +153.1% | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $32.84M | +11.8% | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | $29.38M | n/c | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | $46.77M | -7.6% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $50.62M | -14.5% | 2022-03-08, From 2020-01-01 |
| 2019-12-31 | $59.21M | +43.2% | 2021-03-03, From 2019-01-01 |
| 2018-12-31 | $41.34M | +48.2% | 2020-03-03, From 2018-01-01 |
| 2017-12-31 | $27.90M | +382.5% | 2020-03-03, From 2017-01-01 |
| 2016-12-31 | $5.78M | n/a | 2019-03-19, From 2016-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $145.64M | +75.2% |
| Korsana Biosciences, Inc. (KRSA) | 2025-12-31 | $959.0K | +235.3% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $8.58M | +16.8% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $18.12M | -23.6% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $20.20M | -24.3% |
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | $58.03M | +28.7% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $136.81M | +117.3% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $3.78M | -39.1% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.04M | -84.4% |
Compare DNTH, KRSA, LPCN, GOVX side by side · Screen every company in Pharmaceutical Preparations ↗